Pharmacological treatment of alcohol use disorder. Scientific evidence
01 Pubblicazione su rivista
Perciballi R., Rotondo C., Capriglione I., Iannuzzi S., Attilia M. L., Vitali M., Scamporrino Maria Concetta Marcella, Fiore M., Ceccanti M., Addolorato G., Aliotta V., Barletta G., Battaglia E., Battagliese G., Carito V., Casciani O., Casella P., Cesarini F., Cibin M., Ciccarelli R., Ciolli P., Coriale G., Di Prinzio A., Fagetti R., Falconi E., Federico M., Ferraguti G., Fiorentino D., Gencarelli S., Giuliani A., Greco A., Intaschi G., Janiri L., Lagrutta A., La Torre G., Laviola G., Ledda R., Leggio L., Leonardi C., Loffreda A., Lugoboni F., Macri S., Mancinelli R., Marconi M., Maremmani I., Maviglia M., Messina M. P., Mistretta M., Montesano F., Parisi M., Pascale E., Pisciotta F., Spinnato G., Valchera A., Zavan V., Attilia Fabio, Alessandrini Giovanni
DOI: 10.1708/2925.29414
ISSN: 0035-6484
Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.